可溶性甘露糖受体CD206与血管性血友病因子是识别重症或坏死性急性胰腺炎风险的早期生物标志物
该探索性分析前瞻性纳入81例因急性胰腺炎住院患者(第1天和第3天检测血清sCD206和血浆vWF),并回顾性分析59例症状发作<24小时入住ICU的早期急性胰腺炎患者。患者按研究方案分为非重症水肿性急性胰腺炎组(轻度无器官衰竭或48小时内一过性器官衰竭)和重症/坏死性急性胰腺炎组(持续性器官衰竭>48小时和/或局部并发症)。前瞻性队列17%发生重症/坏死性胰腺炎,ICU队列为56%。入院时sCD206在重症/坏死性组更高(前瞻性:1.57 vs. 0.66 mg/l,P=0.005;ICU:1.76 vs. 1.25 mg/l,P=0.006),而白细胞、C反应蛋白、降钙素原及SOFA、SAPS II、APACHE II无显著差异;vWF抗原入院时升高(前瞻性:375 vs. 257%,P=0.02;ICU:240 vs. 184%,P=0.03)。校正病因和年龄后,sCD206和vWF抗原仍为重症/坏死性急性胰腺炎的预测因素。作者认为sCD206较常规标志物更早识别重症急性胰腺炎风险,需前瞻性研究验证将其纳入评分系统。
要点
- 入院时血清sCD206在重症/坏死性急性胰腺炎患者中高于非重症水肿性患者(前瞻性:1.57 vs. 0.66 mg/l,P=0.005;ICU:1.76 vs. 1.25 mg/l,P=0.006)。
- 入院时血浆vWF抗原在重症/坏死性组升高(前瞻性:375 vs. 257%,P=0.02;ICU:240 vs. 184%,P=0.03),而常规凝血参数未见类似变化。
- 白细胞、C反应蛋白、降钙素原及SOFA、SAPS II、APACHE II在两组间无显著差异。
- 校正病因和年龄后,sCD206和vWF抗原作为连续变量仍为重症/坏死性急性胰腺炎的预测因素。
- 前瞻性队列中重症/坏死性组第3天sCD206较非重症组升高更明显。
适用人群与场景
- 前瞻性队列:81例因急性胰腺炎住院的患者。
- 回顾性队列:59例症状发作<24小时入住ICU的早期急性胰腺炎患者。
诊断标准与关键阈值
- 非重症水肿性急性胰腺炎:轻度急性胰腺炎无器官衰竭,或一过性器官衰竭在48小时内缓解。
- 重症/坏死性急性胰腺炎:重症急性胰腺炎伴持续性器官衰竭>48小时,和/或存在局部并发症。
研究设计与关键结果
- 探索性分析:前瞻性队列81例住院急性胰腺炎患者第1天和第3天检测血清sCD206和血浆vWF;回顾性队列59例症状发作<24小时入住ICU的早期急性胰腺炎患者。
- 前瞻性队列17%发生重症/坏死性胰腺炎,ICU队列56%。
- 入院时sCD206重症/坏死性组 vs. 非重症水肿性组:前瞻性1.57 vs. 0.66 mg/l,P=0.005;ICU 1.76 vs. 1.25 mg/l,P=0.006。
- 入院时vWF抗原重症/坏死性组 vs. 非重症水肿性组:前瞻性375 vs. 257%,P=0.02;ICU 240 vs. 184%,P=0.03。
- 白细胞、C反应蛋白、降钙素原及SOFA、SAPS II、APACHE II在两组间无显著差异。
- 前瞻性队列第3天sCD206在重症/坏死性组较非重症水肿性组升高更明显。
- 校正病因和年龄后,sCD206和vWF抗原作为连续变量仍为重症/坏死性急性胰腺炎的预测因素。
证据类型、等级与局限
- 证据类型:探索性分析(前瞻性队列联合回顾性队列)。
- 局限:作者指出需前瞻性研究探讨将早期或重复测量纳入现有评分系统能否更好识别并发症风险增高的急性胰腺炎患者。
对床旁实践的改变
- 作者认为sCD206较常规炎症和凝血标志物更早识别重症急性胰腺炎风险。
- 作者建议需前瞻性研究探讨将早期或重复测量纳入现有评分系统能否更好识别并发症风险增高的患者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In acute pancreatitis (AP), microcirculatory dysfunction and leukocyte activation contribute to organ damage, inflammation, and mortality. Given the role of macrophage activation, monocyte recruitment, and microthrombus formation in the early pathogenesis of AP, we examined the macrophage activation marker soluble mannose receptor (sCD206) and the endothelial function marker von Willebrand factor (vWF) in patients admitted for AP.
METHODS: In an exploratory analysis, serum sCD206 and plasma vWF were prospectively analyzed on day 1 and day 3 in 81 patients with AP admitted to the hospital. In addition, blood samples from 59 patients with early AP admitted to the intensive care unit and symptom onset < 24 h were retrospectively analyzed. Patients were dichotomized as per study protocol into two groups: (i) "non-severe edematous AP" including patients with mild AP without organ failure and patients with transient organ failure that resolves within 48 h and (ii) "severe/necrotizing AP" including patients with severe AP and persistent organ failure > 48 h and/or patients with local complications.
RESULTS: In the prospective cohort, 17% developed severe/necrotizing pancreatitis compared with 56% in the ICU cohort. Serum concentrations of sCD206 on admission were higher in patients with severe/necrotizing AP than in patients with non-severe edematous AP (prospective: 1.57 vs. 0.66 mg/l, P = 0.005; ICU: 1.76 vs. 1.25 mg/l, P = 0.006), whereas other inflammatory markers (leukocytes, C-reactive protein, procalcitonin) and disease severity (SOFA, SAPS II, APACHE II) did not show significant differences. Patients with severe/necrotizing AP had a greater increase in sCD206 than patients with non-severe edematous AP at day 3 in the prospective cohort. In contrast to routine coagulation parameters, vWF antigen levels were elevated on admission (prospective cohort: 375 vs. 257%, P = 0.02; ICU cohort: 240 vs. 184%, P = 0.03). When used as continuous variables, sCD206 and VWF antigen remained predictors of severe/necrotizing AP after adjustment for etiology and age in both cohorts.
CONCLUSIONS: sCD206 identifies patients at risk of severe AP at earlier timepoints than routine markers of inflammation and coagulation. Prospective studies are needed to investigate whether incorporating early or repeated measurements into the existing scoring system will better identify patients at increased risk for complications of AP.
参考来源
- Reuken PA, Brozat JF, Quickert S, et al. Soluble mannose receptor CD206 and von Willebrand factor are early biomarkers to identify patients at risk for severe or necrotizing acute pancreatitis. J Intensive Care. 2022. PMID: 35690841. doi:10.1186/s40560-022-00619-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。